Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Yamazaki, Masahiro ^a   Hasegawa, Goji ^a   Majima, Saori ^a   Mitsuhashi, Kazuteru ^a   Fukuda, Takuya ^a   Iwase, Hiroya ^a   Kadono, Mayuko ^a   Asano, Mai ^a   Senmaru, Takafumi ^a   Tanaka, Muhei ^a   Fukui, Michiaki ^a   Nakamura, Naoto ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Cardiovascular disease; Continuous glucose monitoring; Glimepiride; MAGE

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; C REACTIVE PROTEIN; GLIMEPIRIDE; GLUCOSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REPAGLINIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; JAPANESE (PEOPLE); MALE; MONOTHERAPY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POSTPRANDIAL STATE; PRIORITY JOURNAL; TREATMENT DURATION; URINALYSIS;

EID: 84901326782     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-54     Document Type: Article

References (24)

1. Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Pravenec M, Kajiya T, Zídek V, Landa V, Mlejnek P, Simáková M, Silhavý J, Malínská H, Oliyarnyk O, Kazdová L, Fan J, Wang J, Kurtz TW, Hypertension 2011 57 4 731 737 10.1161/HYPERTENSIONAHA.110.164350 21357282
2. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arima H, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, Hata J, Matsumura K, Iida M, Kiyohara Y, Arterioscler Thromb Vasc Biol 2008 28 7 1385 1391 10.1161/ATVBAHA.107.157164 18403728
3. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. Ridker PM, Hennekens CH, Buring JE, Rifai N, N Engl J Med 2000 342 836 843 10.1056/NEJM200003233421202 10733371 (Pubitemid 30165206)
4. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Ridker PM, Buring JE, Cook NR, Rifai N, Circulation 2003 107 3 391 397 10.1161/01.CIR.0000055014.62083.05 12551861
5. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Nishikawa T, Sasahara T, Kiritoshi S, Sonoda K, Senokuchi T, Matsuo T, Kukidome D, Wake N, Matsumura T, Miyamura N, Sakakida M, Kishikawa H, Araki E, Diabetes Care 2003 26 1507 1512 10.2337/diacare.26.5.1507 12716813 (Pubitemid 36929187)
6. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Celliello A, Davidson J, Hanefeld M, Leiter L, Monnier L, Owens D, Tajima N, Tuomilehto J, Nutr Metab Cardiovasc Dis 2006 16 453 456 10.1016/j.numecd.2006.05.006 16934443 (Pubitemid 44466389)
7. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D, Diabetes 2008 57 5 1349 1354 10.2337/db08-0063 18299315
8. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C, JAMA 2006 295 14 1681 1687 10.1001/jama.295.14.1681 16609090
9. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freyse EJ, Hovorka R, Salzsieder E, Diabetes Care 2009 32 6 1058 1062 10.2337/dc08-1956 19244086
10. Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus. Li Y, Xu L, Shen J, Ran J, Zhang Y, Wang M, Yan L, Cheng H, Fu Z, Diabetes Res Clin Pract 2010 88 1 42 47 10.1016/j.diabres.2009. 12.017 20060192
11. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE, Diabetes Care 2001 24 6 983 988 10.2337/diacare.24.6.983 11375357 (Pubitemid 33716363)
12. Effects of repaglinide on oxidative stress in tissues of diabetic rabbits. Gumieniczek A, Diabetes Res Clin Pract 2005 68 2 89 95 10.1016/j.diabres.2004.09.018 15860235 (Pubitemid 40602614)
13. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in. Zhang H, Bu P, Xie YH, Luo J, Lei MX, Mo ZH, Liao EY, Chin Med J (Engl) 2011 124 2 172 176 21362360
14. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. Stephens JW, Bodvarsdottir TB, Wareham K, Prior SL, Bracken RM, Lowe GD, Rumley A, Dunseath G, Luzio S, Deacon CF, Holst JJ, Bain SC, Diabetes Res Clin Pract 2011 94 2 199 206 10.1016/j.diabres.2011.07.014 21835486
15. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients-a randomized controlled double-blind and double-dummy multicentre clinical trial. Li J, Tian H, Li Q, Wang N, Wu T, Liu Y, Ni Z, Yu H, Liang J, Luo R, Li Y, Huang L, Diabetes Obes Metab 2007 9 4 558 565 10.1111/j.1463-1326.2006.00638.x 17587398 (Pubitemid 47018519)
16. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Shramm TK, Gislason GH, Vaag A, Rasumussen JN, Folke F, Hansen ML, Fosbol EL, Kober L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C, Eur Heart J 2011 32 15 1900 1908 10.1093/eurheartj/ehr077 21471135
17. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. Esposito K, Ciotola M, Carleo D, Schisano B, Sardelli L, Di Tommaso D, Misso L, Saccomanno F, Ceriello A, Giugliano D, J Clin Endocrinol Metab 2008 93 4 1345 1350 10.1210/jc.2007-2000 18198229 (Pubitemid 351519731)
18. Correlation between glucose fluctuations and carotid intima-media thickness in type 2 diabetes. Chen XM, Zhang Y, Shen XP, Huang Q, Ma H, Huang YL, Zhang WQ, Wu HJ, Diabetes Res Clin Pract 2010 90 1 95 99 10.1016/j.diabres.2010.05.004 20605247
19. A1c variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Wadan J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH, Diabetes 2009 58 2649 2655 10.2337/db09-0693 19651819
20. Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study. Rizzo MR, Barbieri M, Grella R, Passariello N, Barone M, Paolisso G, Diabetes Metab 2004 30 1 81 89 10.1016/S1262-3636(07)70093-9 15029102 (Pubitemid 38418947)
21. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Rizzo MR, Barbieri M, Grella R, Passariello N, Paolisso G, Diabetes Metab 2005 31 3 Pt 1 255 260 16142016 (Pubitemid 40961522)
22. Acute and chronic fluctuations in blood glucose levels can increase oxidative stress in type 2 diabetes. Chang C, Hsieh C, Hung J, Hung I, Acta Diabetol 2012 49 171 177 10.1007/s00592-012-0398-x
23. Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. The NAVIGATOR Study Group, N Engl J Med 2010 362 16 1477 1490 20228403
24. Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus. Kawamori R, Kaku K, Hanafusa T, Kashiwara D, Kageyama S, Hotta N, JDI 2012 3 3 302 308